CMT Research Foundation funds Shift to explore novel series of drugs created to control the expression of PMP22 gene Overland Park: In late January, the CMT Research Foundation (CMTRF) announced a partnership with Shift Pharmaceuticals to further research in treatments for CMT1A, a familiar form of Charcot-Marie-Tooth (CMT). Charcot-Marie-Tooth type 1A, or better known as … Continue reading Shift Pharmaceuticals partners with CMT Research Foundation to further research CMT1A treatment